IBM's OpenPOWER Group is the organization that includes high performance computing (HPC) within the IBM Systems Group. This group is responsible for the strategy, marketing and identification of areas that can benefit from IBM's high end technology. The life sciences is such an area, and IBM is and will continue to bring valued solutions to life sciences.
IBM's Research is a partner with IBM's HPC and OpenPOWER on developing the next generation of high performance data centric computers. In addition, the Research Division has many groups investigating numerous application areas in collaboration with IBM's customers and partners in the life sciences. This includes IBM Research’s Data Centric Solutions and Computational Biology Center.
QuartzBio, part of Precision for Medicine, is a multiomics data integration and interrogation platform. Life science companies use QuartzBio to unravel biomarker and meta-data to generate actionable, analytic-ready data sets. QuartzBio applies machine learning to analyze biological and clinical data streams, extracting knowledge and insights that accelerate the development pathway. The QuartzBio platform is the first platform to successfully integrate diverse biomarker data with machine learning and computational biology based approaches for insight generation — making the complex connections within clinical data ecosystems a reality. For more information, please visit: www.quartzbio.com
SomaLogic® was founded in 2000 by Larry Gold, with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. Building on the previous decade of aptamer research, SomaLogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. Our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare. See more at: https://somalogic.com/About-Us/
Biodesix® is a fully-integrated lung cancer diagnostic solutions company. Our blood-based tests leverage genomics and proteomics to uncover individualized insights about tumor biology and the patient’s immune response. Biodesix design and development teams use a specific machine learning approach to develop tests for researchers, bio-pharma partners, and clinicians. Recent clinical data show that the Biodesix test development approach, which utilizes the circulating proteome, provides unique and important information on the efficacy of immunotherapies and targeted agents. On market Nodify XL2™ GeneStrat® and VeriStrat® tests are performed in regulated laboratories in Boulder, CO and Seattle, WA, providing swift results for patients and their providers. For more information, please visit www.biodesix.com.